Comparison of biphasic insulin aspart 30 given three times daily or twice daily in combination with metformin versus oral antidiabetic drugs alone in patients with poorly controlled type 2 diabetes: A 16-week, randomized, open-label, parallel-group trial conducted in russia
References (32)
- et al.
Insulins today and beyond
Lancet
(2001) - et al.
Long-term efficacy and safety of biphasic insulin aspart 30 in patients with type 2 diabetes
Eur J Intern Med
(2004) Oral antidiabetic agents: 2004
Med Clin North Am
(2004)- et al.
Twice-daily biphasic insulin aspart 30 versus biphasic human insulin 30: A double-blind crossover study in adults with type 2 diabetes mellitus
Clin Ther
(2002) - et al.
Starting patients with type 2 diabetes on insulin therapy using once-daily injections of biphasic insulin aspart 70/30, biphasic human insulin 70/30, or NPH insulin in combination with metformin
J Diabet Complications
(2003) - et al.
Treatment satisfaction after commencement of-insulin in Type 2 diabetes
Diabetes Res Clin Pract
(2004) When oral agents fail: Practical barriers to starting insulin
Int J Obes Relat Metab Disord
(2002)- et al.
The treat-to-target trial: Randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients
Diabetes Care
(2003) Timely initiation of basal insulin
Am J Med
(2004)Basal insulin supplementation in type 2 diabetes: Refining the tactics
Am J Med
(2004)
The possible role of postprandial hyperglycaemia in the pathogenesis of diabetic complications
Diabetologia
Contributions of fasting and postprandial glucose increments to the overall di-urnal hyperglycemia of type 2 diabetic patients: Variations with increasing levels of HbA(lc)
Diabetes Care
The relationship of postprandial glucose to HbA1c
Diab Metab Res Rev
Postprandial hyperglycemia and diabetes complications: Is it time to treat?
Diabetes
Clinical significance, pathogenesis, and management of postprandial hyperglycemia
Arch Intern Med
Optimal glycemic control in type 2 diabetes mellitus: Fasting and postprandial glucose in context
Arch Intern Med
Cited by (28)
Quality of life, patient satisfaction, and cardiovascular outcomes of the randomised 2 x 3 factorial Copenhagen insulin and Metformin therapy (CIMT) trial – A detailed statistical analysis plan
2023, Contemporary Clinical Trials CommunicationsImprovements in quality of life associated with insulin analogue therapies in people with type 2 diabetes: Results from the A <inf>1</inf>chieve observational study
2011, Diabetes Research and Clinical PracticeMultiple HbA1c targets and insulin analogues in type 2 diabetes: A systematic review
2011, Journal of Diabetes and its ComplicationsTreatment regimens with insulin analogues and haemoglobin A1c target of <7% in type 2 diabetes: A systematic review
2011, Diabetes Research and Clinical PracticeCitation Excerpt :If a trial reported the number of episodes in each group or reported an event rate in a form other than episodes per patient per 30 days, we converted this information into episodes per patients per 30 days. We identified 2650 citations, of which we excluded 2508: reviews, recommendations, guidelines, observational studies, letters, comments, editorials, trials without relevant comparisons; we reviewed 126 citations and selected 48 [19–66] for inclusion in our analysis. Thirty three trials were eligible but not reported the primary outcome; the remaining 45 trials were excluded for the following reasons: not RCT n = 8; duplicate publications n = 6; sequential design n = 2; treatment duration <3 months n = 9; study arm <30 patients n = 12; non-insulin analogues n = 4; retrospective study n = 1; mixed type 1 and type 2 diabetic patients n = 2; mixed human insulin and analogues in the same regimen n = 1.
Initiating insulin in patients with type 2 diabetes
2012, CMAJ. Canadian Medical Association JournalCitation Excerpt :In our meta-analysis, we found no significant reduction in HbA1c with a combination of an oral antihyperglycemic agent and insulin (−0.14%, 95% CI −0.36 to 0.08; n = 2566);18,22,31,33,37–39,45,54,77,84–97 this effect was not moderated by class of oral antihyperglycemic agent or by insulin regimen. However, combination therapy was associated with significantly less weight gain (−0.83 kg, 95% CI −1.32 to −0.33; n = 2060)18,22,31,33,37–39,45,54,55,87–89,91,92,94–96 and significantly lower insulin doses (−17.7 units, 95% CI −26.1 to −9.2; n = 1308).18,31,33,37,39,54,87–89,91,92,94,95,97 It was also possibly associated with a reduced risk of hypoglycemia (OR 0.75, 95% CI 0.56 to 1.00; n = 838).22,33,39,84
Effects of Metabolic Medicine and Metabolic Surgery on Patient-Reported Outcomes Among Patients with Type 2 Diabetes
2022, Metabolic Syndrome and Related Disorders